National Academies Press: OpenBook

Defining the Mandate of Proteomics in the Post-Genomics Era: Workshop Report (2002)

Chapter: Appendix C: Workshop Participants

« Previous: Appendix B: Symposium Agenda
Suggested Citation:"Appendix C: Workshop Participants." National Research Council. 2002. Defining the Mandate of Proteomics in the Post-Genomics Era: Workshop Report. Washington, DC: The National Academies Press. doi: 10.17226/10560.
×
Page 40
Suggested Citation:"Appendix C: Workshop Participants." National Research Council. 2002. Defining the Mandate of Proteomics in the Post-Genomics Era: Workshop Report. Washington, DC: The National Academies Press. doi: 10.17226/10560.
×
Page 41
Suggested Citation:"Appendix C: Workshop Participants." National Research Council. 2002. Defining the Mandate of Proteomics in the Post-Genomics Era: Workshop Report. Washington, DC: The National Academies Press. doi: 10.17226/10560.
×
Page 42
Suggested Citation:"Appendix C: Workshop Participants." National Research Council. 2002. Defining the Mandate of Proteomics in the Post-Genomics Era: Workshop Report. Washington, DC: The National Academies Press. doi: 10.17226/10560.
×
Page 43
Suggested Citation:"Appendix C: Workshop Participants." National Research Council. 2002. Defining the Mandate of Proteomics in the Post-Genomics Era: Workshop Report. Washington, DC: The National Academies Press. doi: 10.17226/10560.
×
Page 44

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

APPENDIX C WORKSHOP PARTTCIPANTS Ruedi Aebersold, University of Washington Mayada Akil, National Institutes of Health N. Leigh Anderson, Large Scale Biology Corporation Norman Anderson, Large Scale Biology Corporation Phi! Andrews,University of Michigan Wilhelm Ansorge, European Molecular Biology Laboratory Ettore Appella, National Cancer Institute Rolf Apweiler, European Bioinformatics Institute Cheryl Arrowsmith, University of Toronto Patsy Babbitt, University of California, San Francisco Thomas Baldwin, University of Arizona Michael Baldwin, University of California, San Francisco Mary Joy Ballantyne, Institute of Medicine Rudy Baum, Chemical & Engineering News Walter Blackstock, Celizome AG Steve Those, Bio-Rad Laboratories, Inc. Ralph Bradshaw, University of California, Irvine Thomas Brady, IBM Life Sciences Solutions Steven Brown, University of Delaware Gregory Brown, Adams, Harkness & Hill, Tnc. Eugene Bruce, National Science Foundation Alma Burlingame, University of California, San Francisco Allen Bush, University of Maryland-Baltimore Malcolm Byrnes, Howard University College of Medicine Dolores Cahill, Max-Planck Institute of Molecular Genetics Gerald CarIson, University of Missouri-Kansas City Donald Carison, University of California, Davis Marvin Cassman, National Institute of General Medical Sciences Julio Cells, Institute for Cancer Biology and Danish Centre for Human Genome Research Ron Cerny, University of Nebraska-Lincoin Brian Chait, The Rockefeller University Donald Chambers, University of Illinois at Chicago Kathy Champion, Genentech, Inc. Parag Chitnis, National Science Foundation Brian Clark, University of Aarhus Eleazar Cohen, National Institutes of Health Rhonna Cohen, University of Illinois at Chicago Dean Cole, U.S. Department of Energy Roberta Coleman, University of Delaware Patrick Coleman, 3M Company C-]

Francis Collins, National Human Genome Research Institute Christine Colvis, National Institutes of Health Marguente Coomes, Howard University College of Medicine Ben Cravett, Scripps Research Institute Michael Cusanovich, University of Arizona Matthew Davison, Aventis Pharmaceuticals Alison Deckhut, National Institutes of Health David DeMarini, U.S. Environmental Protection Agency Longwen Deng, George Washington University Medical School Edward Dennis, University of California, San Diego Robert Eades, IBM Life Sciences Solutions Charles Edmonds, National Institute of General Medical Sciences Jonathan Epstein, National Institutes of Health Adam Felsenfeld, National Human Genome Research Institute Madalyn Freund, GeneProt, Inc. Felix Friedberg, Howard University Medical School Bruce Futcher, SUNY at Stony Brook Tom Gadek, Genentech, Inc. David Galas, Keck Graduate Institute of Applied Life Sciences Daniel Gallahan, National Cancer Institute Pamela Gamble, National Research Council Donita Garland, National Eye Institute Hellen Gelband, Institute of Medicine John Gerit, University of Illinois Misrak Gezmu, National Institutes of Health Bradford Gibson, Buck Institute of Age Research Maria Giovanni, National Institutes of Health Gary Giulian, National Institutes of Health Allan Goldstein, George Washington University Medical Center Andrew Gooley, Proteome Systems, Ltd. David Gorenstein, University of Texas Medical Branch Judith Greenberg, National Institutes of Health lack Greenblatt, University of Toronto Marvin Hackert, University of Texas at Austin William Hancock, Journal of Proteome Research Eva Harris, University of California, Berkeley Gerald Hart, John Hopkins School of Medicine Richard Helm, Virginia Tech Preston Hensley, Pfizer John Hobbs, Beckman Coulter, Inc. Denis Hochstrasser, University of Geneva Scott Hutton, ChemNavigator Richard Ikeda, National Institutes of Health Warren Jones, National Institutes of Health Robert Kaiser, Prolinx, Inc. Thea Kalebic, National Cancer Institute C-2

Izet Kapetanovic, National Cancer Institute km Karam, Tulane University Arthur Katz, U.S. DeparLnent of Energy Peter Kennelly, Virginia Tech George Kenyon, University of Michigan Jack Kirsch, University of California, Berkeley Mark Knepper, National Heart, Lung & Blood Institute John Kozarich, Activx Biosciences Joshua LaBaer, Harvard Medical School Linda Lambert, National Institutes of Health David Lamb eth, Emory University Medical School Frank Laukien, Bruker Daltonics Claude Lenfant, National Heart, Lung & Blood Institute William Lennarz, SUNY at Stony Brook Thomas Leyh, Albert Einstein College of Medicine Mary Lopez, Proteome Systems Ltd. Anthony Macaluso, National Institute of Allergy & Infectious Disease Anil MadJukuri, George Washington University Edward Maggio, Structural Bioinformatics Inc. Nina Mani, Institute of Medicine Kenneth Mann, University of Vermont Joel Martin, Forward Ventures Stephen Martin, Applied Biosystems David Martin, Jr., EOS Biotechnology, Inc. Hiroyuki Matsumoto, University of Oklahoma Health Sciences Center Gerald McLaughlin, National Institutes of Health Djamel Me~jahed, National Cancer Institute Noelle Metting, U.S. Department of Energy Steve Michnick, Universite de Montreal Darren Monchkton, The University of Glasgow Walter Moos, Mitokor Richard Moms, National Institutes of Health James Myers, Pacific Northwest National Laboratory Kenneth Neet, Finch UHS/Chicago Medical School Robert Negm, National Cancer Institute Karoly Nikolich, AGY Therapeutics James Nolan, Tulane University, School of Medicine John Norvell, National Institutes of Health Susan O1d, National Heart, Lung & Blood Institute Jong Park, Medical Research Council Scott Patterson, Celera Genomics Cloud Paweletz, U.S. Food and Drug Administration Rainer Pepperkok, EMBE Heidelbrg Gregory Petsko, Brandeis University Patricia Powell, National Institutes of Health Thierry Rabilloud, CNRS C-3

.- Kal Ramnarayan, Structural Bioinformatics, Inc. Urs Regenass, Discovery Partners International Allen Rhoads, Howard University, College of Medicine Tim Riley, Micromass, Inc. Dagmar Ringe, Brandeis University Gerald Rubin, Howard Hughes Medical Institute M. Ruffin, Biotechnology Industry Organization James Ryan, American Chemical Society Alan Sachs, Merck Research Laboratory Andrej Sali, Rockefeller University SalvaTore Sechi, National Institutes of Health Opendra Shanna, National Institutes of Health Laura Sheahan, National Research Council Douglas Sheeley, National Institutes of Health Marilee Shelton, National Research Council Ben Shen, Genentech, Inc. Miho Shimizu, Johns Hopkins University Michael Silber, Pfizer Kimmen Sjolander, University of California, Berkeley Thomas Smith, Howard University Sylvia Spengler, National Science Foundation Christopher Spivey, Human Proteome Organisation Su~hir Srivastava, National Cancer Institute Ken Standing, University of Manitoba Robert Star, National Institutes of Health Gordon Strachan, University of Pennsylvania John Stults, Genentech, Inc. Hisaaki Taniguchi, Harima Institute at SPring-8 David Thomassen, U.S. Department of Energy David U'Prichard, 3-Dimensional Pharmaceuticals Jesus Valenzuela, National Institutes of Health Ruth Van Bogelen, Pfizer Alain Van Dorsselaer, Louis Pasteur University & CARS Thomas Vanaman, University of Kentucky Medical Center Thomas Vanaman, University of Kentucky Akos Vertes, George Washington University Marvin Vestal, Applied Biosystems Marc Vidal, Dana-Farber Cancer Institute Richard Wagner, Phylos, Inc. John Walker, Medical Research Council, Cambridge UK Wendy Wang, National Cancer Institute Scott Warder, Abbott Laboratories Mary Warner, American Chemical Society Scott Weidman, National Research Council Robert Wells, Texas A&M University Richard Whitehead, Otsuka Maryland Research Institute C-4

John Wiktorkowicz, Lynx Therapeutics, Inc. Richard Wolfenden, University of North Carolina James Wong, Beckman Coulter, Inc. Tamae Wong, National Research Council C-5

Defining the Mandate of Proteomics in the Post-Genomics Era: Workshop Report Get This Book
×
 Defining the Mandate of Proteomics in the Post-Genomics Era: Workshop Report
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Research in proteomics is the next logical step after genomics in understanding life processes at the molecular level. In the largest sense proteomics encompasses knowledge of the structure, function and expression of all proteins in the biochemical or biological contexts of all organisms. Since that is an impossible goal to achieve, at least in our lifetimes, it is appropriate to set more realistic, achievable goals for the field. Up to now, primarily for reasons of feasibility, scientists have tended to concentrate on accumulating information about the nature of proteins and their absolute and relative levels of expression in cells (the primary tools for this have been 2D gel electrophoresis and mass spectrometry). Although these data have been useful and will continue to be so, the information inherent in the broader definition of proteomics must also be obtained if the true promise of the growing field is to be realized. Acquiring this knowledge is the challenge for researchers in proteomics and the means to support these endeavors need to be provided. An attempt has been made to present the major issues confronting the field of proteomics and two clear messages come through in this report. The first is that the mandate of proteomics is and should be much broader than is frequently recognized. The second is that proteomics is much more complicated than sequencing genomes. This will require new technologies but it is highly likely that many of these will be developed. Looking back 10 to 20 years from now, the question is: Will we have done the job wisely or wastefully?

READ FREE ONLINE

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  6. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  7. ×

    View our suggested citation for this chapter.

    « Back Next »
  8. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!